Sol-Gel Hits Last Patient Last Visit in Pivotal Phase 3 Gorlin Syndrome Trial
SLGL has more than doubled off its 52-week low of $23.15.
Summary
Sol-Gel completed the last patient last visit in its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome, a rare genetic disorder causing basal cell carcinomas. The trial enrolled 113 patients, with 102 completing the 12-month treatment period. Database lock and statistical analysis are now underway, with top-line results expected in late November 2026. This milestone de-risks the program's timeline and sets a concrete catalyst for the stock. The company remains blinded, so no efficacy data is available yet. Opaleye Management has been aggressively accumulating shares over the past two months, suggesting institutional conviction ahead of the readout.
At the time of this announcement, SLGL was trading at $63.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.7M. The 52-week trading range was $23.15 to $97.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.